Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Elderly Acute Lymphoblastic Leukemia: Low-Dose Chemotherapy and Immunotherapy Combinations.","authors":"Perrine Moyer, Aude-Marie Fourmont, Lucie Freiman, Philippe Rousselot, Patrice Chevallier","doi":"10.1016/j.clml.2025.06.001","DOIUrl":"https://doi.org/10.1016/j.clml.2025.06.001","url":null,"abstract":"<p><p>There is an unmet medical need for the treatment of elderly patients with acute lymphoblastic leukemia (ALL), as only a minority of them achieves long-term survival with current anti-ALL chemotherapy. Here, the recent management of these patients is discussed, including current approaches and future directions, as novel agents developed for refractory/relapsed ALL are now being incorporated into front-line therapies with very promising results. The manuscript will sequentially consider Philadelphia chromosome (Ph) negative ALL, then Ph+ and finally T-ALL. Accordingly, novel strategies using chemo-free approaches and new drugs such as inotuzumab ozogamicin, blinatumomab, venetoclax, tyrosine kinase inhibitors and CAR T-cells will be discussed.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in Myeloma.","authors":"Clifton C Mo, Yuxin Liu, Monique A Hartley-Brown, Omar Nadeem, Shonali Midha, Paul G Richardson","doi":"10.1016/j.clml.2025.06.003","DOIUrl":"https://doi.org/10.1016/j.clml.2025.06.003","url":null,"abstract":"<p><p>High-dose melphalan with autologous stem cell transplant (HDM-ASCT) remains a standard-of-care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), with data from randomized studies demonstrating progression-free survival (PFS) benefit with transplant versus nontransplant approaches. However, with increasing overall survival (OS) in this setting, associated with the substantial efficacy of triplet and quadruplet regimens and multiple novel treatment approaches, strategic considerations are key, together with a holistic approach taking into account patients' preferences and needs, for treatment decision-making. In this context, the approach of deferring HDM-ASCT is being increasingly considered, associated with various drivers. Rationales for deferring HDM-ASCT include the acute and long-term toxicities and sequelae associated with undergoing transplant, such as the increased mutational burden and elevated risk of secondary leukemia arising following HDM. Given these downsides, another driver for considering deferred HDM-ASCT is that substantial variability in magnitude of PFS benefit has been seen across patient subgroups. Furthermore, despite significant PFS benefit, randomized studies have not shown OS benefit in the era of triplet induction/consolidation and multiple active treatment options at relapse. Additionally, very high rates of minimal residual disease (MRD)-negative responses have been demonstrated with emerging standard-of-care quadruplet induction regimens for NDMM, facilitating potential HDM-ASCT-sparing, MRD-adapted treatment approaches. Finally, novel therapies such as chimeric antigen receptor (CAR) T-cell and bispecific antibody therapies are beginning to be investigated as upfront alternatives in transplant-eligible patients. Thus, associated with these multiple drivers, late or deferred HDM-ASCT is emerging as a potential standard-of-care approach for select transplant-eligible patients with NDMM.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasmablastic Lymphoma-A Crosstalk Between Myeloma and Lymphoma.","authors":"Maha Hameed, Ahmad Iftikhar, Sakina Abbas, Zohaa Faiz, Fathima Shehnaz Ayoobkhan, Sameer Siddiqui, Muhammad Affan Elahi, Shaista Khadim, Faiz Anwer, Muhammad Husnain","doi":"10.1016/j.clml.2025.05.024","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.024","url":null,"abstract":"<p><p>Plasmablastic lymphoma (PBL) is a rare type of large B-cell lymphoma that primarily affects immunocompromised individuals, often associated with viral infections such as Human Immunodeficiency Virus (HIV) and Epstein-Barr Virus (EBV). The diagnosis of PBL is often difficult to ascertain due to its overlapping clinical and pathological features with multiple myeloma and large B cell lymphoma. The primary organs of involvement are typically the gastrointestinal system, lymph nodes, oral mucosa, with some involvement of the skin. This review explores the critical aspects of plasmablastic lymphoma, including its clinical features, diagnosis, treatment options, and the latest advancements for this rare disease. Understanding plasmablastic lymphoma is necessary for healthcare professionals and patients alike to improve the outcomes and quality of life for those affected by this aggressive form of lymphoma.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma.","authors":"Izidore S Lossos","doi":"10.1016/j.clml.2025.05.021","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.021","url":null,"abstract":"<p><p>Marginal zone lymphoma (MZL) is a heterogeneous disease representing 7% to 10% of non-Hodgkin lymphomas (NHL). There are no clear guidelines defining the need for treatment initiation and no standardized therapeutic approach for patients with MZL. Previously, many treatments were extrapolated from clinical trials that mainly enrolled patients with follicular lymphoma and did not have statistical power to show treatment efficacy specifically in MZL patients. Currently, the field is moving toward conducting specific trials in MZL patients with specific inclusion criteria for each MZL subtype, assessing response distinctively in FDG avid and nonavid MZL tumors and using MZL-relevant primary endpoints. Herein I briefly describe these changes, summarize previous therapeutic studies in MZL and present preliminary publicly available data on novel emerging treatments, including bispecific antibodies, antibody drug conjugates and novel targeted therapies.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monoclonal Gammopathies in Africa.","authors":"Abiola Bolarinwa, Lateef Odukoya, Francis Buadi, Vincent Rajkumar, Shaji Kumar, Celine Vachon, Lily Paemka, Linda B Baughn, Joselle M Cook","doi":"10.1016/j.clml.2025.05.023","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.023","url":null,"abstract":"<p><p>People of African descent have a reported higher incidence of multiple myeloma (MM) and increased prevalence of its precursor conditions, monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Despite this, research focusing on people of African descent remains sparse. Even in the absence of robust studies across African populations, major disparities are consistently reported. West Africans and South African Black men have a higher prevalence of MGUS than individuals of European descent. MM has been shown to occur in African individuals at a younger age of diagnosis compared to European individuals, with a relatively higher proportion of females (M/F ∼1 vs. 1.4 in Europeans), delayed diagnosis (symptoms to diagnosis 10-12 months), and a higher prevalence of bone disease at presentation. This review summarizes the existing literature on monoclonal gammopathies for African people and highlights critical gaps in our understanding of the disease within the diverse African population. Importantly, differences in disease biology, with respect to cytogenetic and immunologic differences, which contribute to disparate disease outcomes are discussed. Concerted efforts to bridge knowledge gaps through collaborative research initiatives, both within and beyond the African continent, are urgently needed.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, Canada.","authors":"Victor H Jimenez-Zepeda, Mariet Mathew Stephen, Henry Chan, Winson Y Cheung","doi":"10.1016/j.clml.2025.05.006","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.006","url":null,"abstract":"<p><strong>Background: </strong>Proteasome inhibitors (PI) and immunomodulatory drugs (IMiDs) are important backbones in early line treatments for patients with multiple myeloma (MM). This study examined real-world treatment patterns, clinical outcomes and healthcare resource utilization (HCRU) of double-class exposed (DCE) patients with MM after prior PI and IMiD-based treatment.</p><p><strong>Methods: </strong>DCE patients were identified using integrated administrative databases in the province of Alberta, Canada. DCE patients who commenced subsequent lines of therapy (LOT) between January 2012 and December 2022 were included.</p><p><strong>Results: </strong>Among 831 DCE patients identified to have initiated subsequent LOT during the study period, median age was 68.0 years. IMiD (61%) was the most commonly used therapeutic class after progressing on double-class exposure, followed by PI (39%) and monoclonal antibodies (26%). Attrition rates after first subsequent LOT, defined as death before receiving the next LOT, was 27%, and attrition from second to third subsequent LOT was 30%. Median time to next treatment or death was 12.1 months (95% confidence interval: 10.3-14.1) and median overall survival was 34.4 months (30.3-40.2) from the start of the next subsequent LOT after double-class exposure. healthcare resource utilization (HCRU) during the first year of starting subsequent LOT was high, with a median of 1 ED visit, 1 inpatient admission, 30 clinic visits, 3 infusion appointments, 56 unique healthcare encounters. On average, patients spent 42.2 days on laboratory tests.</p><p><strong>Conclusion: </strong>Clinical outcomes among patients with MM initiating postdouble-class exposure treatments remain suboptimal, with high attrition rates and significant healthcare use, highlighting the need for therapies that reduce patient burden.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Does Limited Stage Diffuse Large B-cell Lymphoma Matter?","authors":"Arina Martynchyk, Eliza A Hawkes","doi":"10.1016/j.clml.2025.05.018","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.018","url":null,"abstract":"<p><p>Limited stage diffuse large B-cell lymphoma (LSDLBCL) has excellent outcomes, but progress in management has been plagued by lack of standard definitions and exclusion from many trials evaluating novel agents in advanced stage DLBCL (ASDLBCL) which increasingly target high-risk populations. LSDLBCL definition varies but is most commonly defined as Ann Arbor stage I-II nonbulky disease (< 10 cm). LSDLBCL patient long-term survival exceeds 90% when treated with standard courses (6-8 cycles) of chemoimmunotherapy (CIT). Attempts have therefore been made to minimize CIT toxicity via fewer cycles, employing radiotherapy or positron emission tomography (PET)-adapted CIT instead. This has led to significant variation and complexity in LSDLBCL treatment, not least because LSDLBCL definition and trial eligibility have lacked consistency. Four key dedicated LSDLBCL treatment paradigms have evolved beyond the standard 6-8 RCHOP cycles given to ASDLBCL, such as Combined Modality Treatment (CMT), PET-adapted CMT and PET-directed RT, abbreviated RCHOP for young patients with no poor risk factors and PET-adapted CIT. Greater understanding of the biology and risk profiles of LSDLBCL matters, as does tailoring treatment in this unique disease. Ongoing international collaborative efforts to refine treatment paradigms according to risk are required to improve outcomes in these patients. Novel therapy studies should also be part of the immediate research agenda.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Perspectives on Amyloidosis in India: A Systematic Literature Review.","authors":"Sumeet Mirgh, Uday Yanamandra, Ganesh K Vishvanathan, Sadashivudu Gundeti, Navin Khattry, M Joseph John, Pankaj Malhotra, Hari Menon, Satyaranjan Das, Reena Nair, Velu Nair, Tapan Saikia, Shaji K Kumar","doi":"10.1016/j.clml.2025.05.014","DOIUrl":"10.1016/j.clml.2025.05.014","url":null,"abstract":"<p><strong>Background: </strong>Amyloidosis is a condition characterized by deposition of insoluble protein fibrils in tissues, leading to diverse clinical manifestations. There is limited data addressing amyloidosis from India.</p><p><strong>Objective: </strong>This study aims to systematically review the available clinical data on amyloidosis in India. By synthesizing existing knowledge, the review seeks to identify research gaps that require further exploration.</p><p><strong>Methods: </strong>A systematic review was conducted using the PubMed database to identify English-language articles on amyloidosis from India published between 1959-2023. Additionally, abstracts from international conferences were analyzed. Data extracted were-type of amyloidosis, demographics, clinical presentation, diagnostic methods, and outcomes.</p><p><strong>Results: </strong>The median age at presentation in Indian patients was approximately 10 years younger (50 years) compared to their counterparts in Western countries (60 years), with males comprising 70% of the cases. Renal involvement was the most common, with AA being more prevalent than AL amyloidosis, often secondary to tuberculosis. Cardiac involvement was second most common, affecting 40%-50% of patients. In patients with paraproteinemic neuropathies, AL amyloidosis accounts for the cause in 4% cases. Treatment of AL amyloidosis primarily involved chemotherapy and supportive care, with autologous transplantation underutilized due to resource limitations. Amongst localized amyloidosis, skin was the most common site (68% of all cases).</p><p><strong>Conclusion: </strong>Amyloidosis in India remains a significant and often underdiagnosed condition, with varied presentations and causes. Most data come from retrospective studies, highlighting variability in presentation and outcomes. This review underscores the importance of understanding the disease burden and advancing research to improve outcomes in India.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.","authors":"Benoit Tessoulin, James Harnett, Seok-Goo Cho, Michał Taszner, Tae Min Kim, Silvana Novelli, Jose C Villasboas, Michele Merli, Ana Jiménez-Ubieto, Michelle Poon, David Tucker, Jan Walewski, Shuhua Yi, Yuqin Song, Geoffrey Chong, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Wei Zhang, Laura Magnano Mayer, Elżbieta Iskierka-Jażdżewska, Monica Tani, Jingxian Cai, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Lei Chi, Siddhesh Kamat, Stefano Luminari","doi":"10.1016/j.clml.2025.05.017","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.017","url":null,"abstract":"<p><strong>Background: </strong>In ELM-2, the human CD20 × CD3 bispecific antibody odronextamab was associated with deep, durable responses and a generally manageable safety profile in patients with relapsed/refractory follicular lymphoma (r/r FL).</p><p><strong>Patients and methods: </strong>Prespecified analyses reported herein examined patient-reported outcomes in ELM-2 among 140 patients with r/r FL.</p><p><strong>Results: </strong>Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), patients reported good global health status/quality of life (GHS/QoL), functioning, and low symptom burden at baseline, which were generally maintained. Emotional functioning improved significantly overall, with a clinically meaningful change at week 42. Patients were more likely to report clinically meaningful improvement or maintenance than worsening on QLQ-C30 scales. Median time to definitive deterioration (TTDD) was 22.4 months for GHS/QoL, 22.6 months for role functioning, 19.8 months for social functioning, 16.4 months for cognitive functioning, and not reached for physical functioning or emotional functioning. For each QLQ-C30 symptom scale, median TTDD was > 15 months or not reached. On the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) questionnaire, Lymphoma Subscale (LymS) scores improved significantly overall, with clinically meaningful improvement at weeks 26 and 42, and FACT-G, Trial Outcome Index, and Total Score were maintained. Most patients reported either limited or no bother related to side effects of treatment. Visual analog scale scores of the EQ-5D-3L questionnaire improved significantly overall.</p><p><strong>Conclusion: </strong>In this heavily pretreated, highly refractory population, maintenance or improvement of health-related quality of life, functioning, and symptoms support odronextamab as a potential treatment option in R/R FL.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India.","authors":"Smeeta Gajendra, Tanima Dwivedi, Karthik Bommannan, Ranjit Kumar Sahoo, Nupur Das, Prashant Tembhare, Khaliqur Rahman, Ajay Gogia, Raja Pramanik, Nitin Dayal, Rakhee Kar, Jyoti Kotwal, Sanjeev, Asish Rath, Diksha Dev, Ganesh Kumar Viswanathan, Man Updesh Singh Sachdeva, Mukul Aggarwal, Devasis Panda, Prashant Mehta, Sreejesh Sreedharanunni, Uday Yanamandra, Arun Kumar Arunachalam, Bhausaheb Bagal, Prabhat S Malik, Anil Handoo, Sanjeev Kumar Gupta, Sameer Bakhshi, Atul Sharma, Deepak Kumar Mishra, Pankaj Malhotra, Lalit Kumar, Ritu Gupta","doi":"10.1016/j.clml.2025.05.016","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.016","url":null,"abstract":"<p><strong>Background: </strong>Measurable residual disease (MRD) is becoming a cornerstone in the multiple myeloma (MM) management; however, its implementation in India faces several challenges. This Delphi survey aimed to gather expert consensus on the current practices, and barriers in MRD monitoring in MM in India.</p><p><strong>Methods: </strong>A 3-round Delphi process (2 e-surveys and 1 in-person meeting) was conducted with hematologists, pathologists, and oncologists managing MM in India. Consensus (≥ 75% agreement) led to recommendations for standardized MRD practices.</p><p><strong>Results: </strong>Twenty-five experts participated, agreeing on key protocols: processing first-pull bone marrow aspirates within 24 hours, using a single tube with at least a 10-color panel, acquiring at least 3 million events for 10⁻⁵ sensitivity under proper environmental control, and by adequately trained staff. At least 4 monoclonal antibodies for gating of plasma cells and at least 3 parameters among mast cells, myeloid precursors, hematogones, normal plasma cells, should be used to assess hemodilution. Guidance on modulation of treatment decisions, including maintenance therapy based on MRD status remains inconclusive. Though, there is an agreement that MRD negativity in MM improves survival and lowers relapse risk but currently it does not influence maintenance therapy decisions. MRD testing was advised at postinduction, pre/post-transplant, and annually during maintenance. Challenges identified included protocol variability, interpretation issues, and lack of an external quality assessment program. Experts emphasized the need for advanced flow cytometry training.</p><p><strong>Conclusions: </strong>The findings of this study will guide clinical adoption and future research, particularly for high-risk populations and novel therapies.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}